01.002 RWE TNT JULY 2022 I 25-07-2022

Baseline UK real-world study in ovarian cancer pre-PARPi published

  • A study was published recently on the real-world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors as a result of a collaboration between AstraZeneca and SVMPharma
  • The study, aside from providing a baseline for future evaluations to compare themselves to, produced survival data which complements randomised control trials (RCTs); for example, it described a shorter median overall survival for patients in the real-world than those reported in landmark RCTs
  • “[This study] will be an important benchmark for the future.

” Dr Ros Glasspool, Consultant Medical Oncologist at Beatson West of Scotland Cancer Centre

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at